Breaking Finance News

Cantor Fitzgerald downgraded Mirna Therapeutics (NASDAQ:MIRN) from Buy to Hold in a report released today.

Cantor Fitzgerald has downgraded Mirna Therapeutics (NASDAQ:MIRN) from Buy to Hold in a statement released on 9/21/2016.

On 9/12/2016, HC Wainwright released a statement for Mirna Therapeutics (NASDAQ:MIRN) bumped up the target price from $0.00 to $6.00 that suggested an upside of 1.35%.

Boasting a price of $2.46, Mirna Therapeutics (NASDAQ:MIRN) traded 3.06% higher on the day. With the last stock price close down -50.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Mirna Therapeutics has recorded a 50-day average of $2.98 and a two hundred day average of $4.07. Volume of trade was up over the average, with 61,560 shares of MIRN changing hands over the typical 28,677

Performance Chart

Mirna Therapeutics (NASDAQ:MIRN)

With a total market value of $0, Mirna Therapeutics has with a one year low of $1.82 and a one year high of $11.01 .

A total of 4 equity analysts have released a ratings update on MIRN. Three equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $11.00.

Brief Synopsis About Mirna Therapeutics (NASDAQ:MIRN)

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.